コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ts ranged from 90.2% (caspofungin) to 93.2% (anidulafungin).
2 echinocandins (micafungin, caspofungin, and anidulafungin).
3 No significant change has been observed for anidulafungin.
4 d 99% were inhibited by < or =1 microg/ml of anidulafungin.
5 12/0.5 (95.9%); amphotericin, 0.5/2 (88.3%); anidulafungin, 0.5/2 (97.4%); caspofungin, 0.12/0.5 (98.
6 (304 isolates), flucytosine (254 isolates), anidulafungin (121 isolates), caspofungin (300 isolates)
9 I] or resistant [R]) to both caspofungin and anidulafungin, 52 (83.8%) contained a mutation in fks1 o
10 d by concentrations of < or = 2 microg/ml of anidulafungin (621 isolates tested), caspofungin (1,447
12 her evidence for the spectrum and potency of anidulafungin activity against a large and geographicall
17 silosis, from 0.4% (2004) to 1.8% (2009) for anidulafungin and C. glabrata, from 2.4% (2004) to 5.7%
23 le, voriconazole, posaconazole, caspofungin, anidulafungin, and micafungin) and interpreted the MICs
29 successful in 75.6% of patients treated with anidulafungin, as compared with 60.2% of those treated w
31 Reference susceptibility was determined for anidulafungin, caspofungin, 5-flucytosine, fluconazole,
32 We determined the in vitro activities of anidulafungin, caspofungin, and micafungin against 5,346
33 We determined the in vitro activities of anidulafungin, caspofungin, and micafungin against 526 i
34 to develop interpretive MIC breakpoints for anidulafungin, caspofungin, and micafungin against Candi
35 voriconazole, posaconazole, amphotericin B, anidulafungin, caspofungin, and micafungin against invas
36 dards Institute (CLSI) BMD method M27-A3 for anidulafungin, caspofungin, and micafungin susceptibilit
38 of C. glabrata to fluconazole, voriconazole, anidulafungin, caspofungin, and micafungin were determin
39 each isolate, MICs to FLC and echinocandins (anidulafungin, caspofungin, and micafungin) and FKS1 and
40 ) and 9.3%, 9.3%, and 8.0% were resistant to anidulafungin, caspofungin, and micafungin, respectively
41 percentages of non-WT isolates per year for anidulafungin, caspofungin, and micafungin, respectively
42 qual to the ECV is shown in parentheses) for anidulafungin, caspofungin, and micafungin, respectively
43 isolates inhibited by < or = 2 microg/ml of anidulafungin, caspofungin, and micafungin, respectively
44 al collection of Candida sp. strains against anidulafungin, caspofungin, and micafungin, using CLSI M
45 ity were used for fluconazole, voriconazole, anidulafungin, caspofungin, and micafungin, while a prov
50 B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, and terbinafine.
51 testing was performed against 7 antifungals (anidulafungin, caspofungin, micafungin, fluconazole, itr
52 and Candida glabrata that were resistant to anidulafungin, caspofungin, or micafungin were shown to
53 Echinocandins (caspofungin, micafungin, and anidulafungin) exert their fungicidal activity by inhibi
54 tifungal susceptibility data for micafungin, anidulafungin, fluconazole, and voriconazole against Can
56 ncreased for micafungin (from 0.8% to 7.6%), anidulafungin (from 0.9% to 7.3%), and voriconazole (fro
58 end of intravenous therapy were 73.2% in the anidulafungin group and 61.1% in the fluconazole group (
61 se identified optimum testing conditions for anidulafungin into future versions of the M38 document i
63 nazole monotherapy, combination therapy with anidulafungin led to higher survival in subgroups of pat
64 lates were inhibited by < or =2 microg/ml of anidulafungin (MIC(90), 0.06 microg/ml), micafungin (MIC
65 inocandins were very active against Candida: anidulafungin (MIC50, 0.06 microg/ml; MIC90, 2 microg/ml
69 ta-1,3-D-glucan synthase inhibitors, such as anidulafungin, results in depletion of asci, but not tro
70 ver, cell growth kinetics in the presence of anidulafungin revealed important cues about the in vitro
72 ungin MIC values were compared with those of anidulafungin to determine the percentage of categorical
73 ECV) of 0.12 mug/ml for both caspofungin and anidulafungin to differentiate wild-type (WT) from non-W
74 Categorical agreement ranged from 99.3% (anidulafungin) to 100% (caspofungin, micafungin) and int
75 nstitution (IR)-mediated clearance of PcP in anidulafungin-treated and untreated mice was characteriz
76 numbers of trophic forms were present in the anidulafungin-treated and untreated mice; however, asci
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。